Company intelligence
Immunophotonics, Inc.
Interventional Immuno-Oncology
About Immunophotonics, Inc.
Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.
Verified activity
Signals from Immunophotonics, Inc.
6 published signals
Presence & Recognition
Immunophotonics, Inc. is attending the BioGenerator Startup Connect event during the networking breaks
Reported by Robert Arch
Presence & Recognition
Immunophotonics, Inc. is attending CIRSE 2026 in Copenhagen.
Reported by Immunophotonics, Inc.
Presence & Recognition
Immunophotonics, Inc. President and CEO Robert Arch will attend the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 meeting in Copenhagen.
Reported by Robert Arch
People
Immunophotonics, Inc. appointed Robert H. Arch, Ph.D., as President and Chief Executive Officer.
Reported by Immunophotonics, Inc.
Capital & Finance
Immunophotonics, Inc. closed more than $10 million in Series C financing.
Reported by Immunophotonics, Inc.
Capital & Finance
Immunophotonics, Inc. closed more than $10 million in Series C financing.
Reported by Robert Arch